PureTech Health (PRTC)

PureTech Health PLC, together with its subsidiaries, is a clinical-stage biopharma company developing medicines to modulate the adaptive human system. The company is focused on developing and commercializing differentiated medicines for devastating diseases, including inflammatory, immunological conditions, intractable cancers, lymphatic & gastrointestinal diseases, and neurological and neuropsychological disorders, among others. Its drug development pipeline consists of Deupirfenidone (LYT-100), for the potential treatment of idiopathic pulmonary fibrosis (IPF), LYT-200, SPT-300, an oral drug for depressive disorder, SPT-320, and others. The company's operating segments include Parent Companies & Other, which derives key revenue, Wholly-Owned Programs, and Controlled Founded Entities.

A(z) PureTech Health plc American Depositary Shares (PRTC) részvény after-hours mai árfolyama , ami NaN% after-hours elmozdulást tükröz a piac legutóbbi zárása óta. A vállalat piaci kapitalizációja jelenleg 410,86 M $, a napi kereskedési volumen pedig  részvény. A korábbi záró ár volt.

Készen állsz? Kövesd az alábbi lépéseket, vagy olvasd el útmutatónkat a(z) hogyan vásárolj PureTech Health részvényt a Krakenen, kezdve 10 dollárral.